Le Revenu Y/Y de Amarin Corp est -23.53%
La croissance annuelle des revenus des trois dernières années correspond à la croissance moyenne des revenus d’une année sur l’autre au cours des trois dernières années.
The yearly revenue growth rate is calculated as the percentage change in revenue over the trailing twelve months. For this specific metric, the calculation takes into account a series of the last eight quarterly revenues. The revenue growth is useful for determining the success of the company expanding its main business. Revenue growth of 5% to 10% is usually considered good for large-cap companies. For other companies, a sales growth of over 10% is more desirable.
amarin corporation plc is a biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health. amarin's product development program leverages its extensive experience in lipid science and the potential therapeutic benefits of polyunsaturated fatty acids. vascepa® (icosapent ethyl) is amarin's first fda approved product and is available in the united states by prescription. for more information about vascepa visit www.vascepa.com.